Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 14,150 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
Interventions: Bilastine, Placebo; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more

Conditions: Acute Upper Respiratory Track Infection
Interventions: Guaifenesin, Placebo; Drug · Device
Lead sponsor: Reckitt Benckiser Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Mesa, Arizona • Carmichael, California • Fresno, California + 21 more

Conditions: Cystic Fibrosis
Interventions: CTX-4430, Placebo; Drug
Lead sponsor: Celtaxsys, Inc.; Other
Eligibility: 18 Years to 30 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 39
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 34 more

Conditions: Influenza
Interventions: Influenza virus vaccine (Fluviral), Saline placebo; Biological
Lead sponsor: ID Biomedical Corporation, Quebec; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 7,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 43
States / cities: Sacramento, California • San Francisco, California • Denver, Colorado + 34 more

Conditions: Parkinson Disease
Interventions: Placebo, PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD), PF-06649751 high dose (15 mg QD); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 33
States / cities: Phoenix, Arizona • Arcadia, California • Loma Linda, California + 26 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: RO6889450, Placebo, Risperidone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 24
States / cities: Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more

Conditions: Major Depressive Disorder
Interventions: AV-101, Placebo; Drug
Lead sponsor: VistaGen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Garden Grove, California • Los Angeles, California • National City, California + 18 more

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions: ISL, ULO, BIC/FTC/TAF, Placebo for BIC/FTC/TAF, Placebo to ISL/ULO, ISL/ULO; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 24
States / cities: Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 20 more

Conditions: NAFLD
Interventions: RYI-018, Placebo; Biological
Lead sponsor: Bird Rock Bio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Chula Vista, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: Refractory Hypertension
Interventions: Placebo, TC-5214; Drug
Lead sponsor: Targacept Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: COPD
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 63
States / cities: Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more

Conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions: Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 30
States / cities: Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more

Conditions: Ovarian Cancer, Endometrial Cancer
Interventions: Tc 99m EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Septic Shock
Interventions: Seraph-100 + State of the Art Care, State of the Art Care; Device
Lead sponsor: ExThera Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Brunswick, Georgia • Ann Arbor, Michigan + 5 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Artesia, California • Sacramento, California • Bel Air, Maryland + 5 more

Conditions: Persistent Corneal Epithelial Defect
Interventions: Cenegermin, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more

Conditions: Vitrectomy
Interventions: Utravit High-Speed 10000 cpm Beveled Probe, standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Anterior Uveitis
Interventions: Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%); Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 85 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions: Cinacalcet, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 15
States / cities: Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more

Conditions: Pain, Postoperative
Interventions: Exparel; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
Interventions: GNSC-001, transient immune-modulation, Placebo; Genetic · Drug
Lead sponsor: Genascence Corporation; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Mobile, Alabama • La Mesa, California • San Diego, California + 6 more

Conditions: Menopause
Interventions: Ashoka Bark and Shatavari, Placebo; Dietary Supplement · Other
Lead sponsor: Vidya USA Corporation; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Osteoarthritis
Interventions: CNTX-4975, Placebo; Drug · Other
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 18 more

Conditions: Hepatocellular Carcinoma
Interventions: ThermoDox, 5% Dextrose Solution; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older
Enrollment: 701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 9
States / cities: Los Angeles, California • Jacksonville, Florida • Louisville, Kentucky + 6 more

Search by objective public record fields.

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

Blood Purification for the Treatment of Pathogen Associated Shock

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Post C-Section Pain Control Using EXPAREL

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

Satavari and Ashoka for Menopause (SAM) Study

Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)